₹
4.18
May 24
Business Description
Venmax Drugs & Pharmaceuticals Ltd
ISIN : INE154G01022
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -7.99 | |||||
Debt-to-Equity | -0.54 | |||||
Debt-to-EBITDA | 3.74 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year FCF Growth Rate | -80.1 | |||||
3-Year Book Growth Rate | 38.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.02 | |||||
Quick Ratio | 0.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.83 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | Neg. Equity | |||||
ROA % | 34.1 | |||||
ROIC % | -12.65 | |||||
ROC (Joel Greenblatt) % | 184.31 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 34.83 | |||||
PE Ratio without NRI | 34.83 | |||||
Price-to-Free-Cash-Flow | 1045 | |||||
Price-to-Operating-Cash-Flow | 1045 | |||||
EV-to-EBIT | 29.22 | |||||
EV-to-EBITDA | 26.99 | |||||
EV-to-FCF | 1154.32 | |||||
Price-to-Projected-FCF | 1.9 | |||||
Earnings Yield (Greenblatt) % | 3.42 | |||||
FCF Yield % | 0.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Venmax Drugs & Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | |||
EPS (TTM) (₹) | 0.12 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (₹) | 0 | ||
20-Day SMA (₹) | 4.18 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (₹) | 4.18 - 4.18 | ||
Shares Outstanding (Mil) | 5.24 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Venmax Drugs & Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Venmax Drugs & Pharmaceuticals Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Venmax Drugs & Pharmaceuticals Ltd Frequently Asked Questions
What is Venmax Drugs & Pharmaceuticals Ltd(BOM:531015)'s stock price today?
When is next earnings date of Venmax Drugs & Pharmaceuticals Ltd(BOM:531015)?
Does Venmax Drugs & Pharmaceuticals Ltd(BOM:531015) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |